Clinical trial
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
NCT00069108 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00069108 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer |
| Official title | An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic… |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda] |
| Enrollment | 627 |
| Start date | Jul 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 18, 2003 |
| Last update posted | Apr 1, 2016 |
| Countries | Belgium, Canada, Croatia, Finland, France, Germany, Greece, Israel, Italy, Poland, Puerto Rico, Serbia and 8 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: